TSC-200-A0201 + TSC-204-A0101

TSC-200-A0201 + TSC-204-A0101 is a combination of two autologous, engineered T cell receptor (TCR)-T cell therapies developed by TScan Therapeutics for the treatment of solid tumors. Each component targets a specific tumor antigen presented on HLA molecules: • **TSC-200-A0201** targets human papillomavirus 16 (HPV16) presented on HLA type A*02:01, an oncogenic virus responsible for a significant proportion of cervical and other HPV-related cancers. • **TSC-204-A0101** targets melanoma-associated antigen 1 (MAGE-A1), though the specific HLA restriction for this code is not explicitly stated in the available sources but likely involves common HLA types used in multiplexed therapy[4][5][6]. This combination is part of the "T-Plex" platform, which enables customized multiplexed administration of enhanced affinity, naturally occurring TCR-Ts to address tumor heterogeneity and reduce relapse risk due to target or HLA loss. The therapies are currently being evaluated in Phase 1 clinical trials for various HPV-related and other solid tumors[5][6].